Angiogenesis: a target in solid tumors, also in leukemia?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Hematology. American Society of Hematology. Education Program

• Publication date

  2011-12-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/asheducation-2011.1.1PMID 22160005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

  2011cited by this paper
• Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.

  2011cited by this paper
• Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

  2011cited by this paper
• Molecular mechanisms and clinical applications of angiogenesis

  2011cited by this paper
• Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells

  2011cited by this paper
• Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• VEGF targeted therapy in acute myeloid leukemia.

  2011cited by this paper
• HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.

  2011cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

  2010cited by this paper
• Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.

  2010cited by this paper
• Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

  2010cited by this paper
• Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

  2010cited by this paper
• Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF.

  2010cited by this paper
• Leukemia regression by vascular disruption and antiangiogenic therapy.

  2010cited by this paper
• Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

  2010cited by this paper
• Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors

  2009cited by this paper
• Role and therapeutic potential of VEGF in the nervous system.

  2009cited by this paper
• Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells.

  2009cited by this paper
• Imatinib and beyond—exploring the full potential of targeted therapy for CML

  2009cited by this paper
• FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

  2009cited by this paper
• The leukemic stem cell niche: current concepts and therapeutic opportunities.

  2009cited by this paper
• “Antimyeloangiogenic” Therapy for Cancer by Inhibiting PlGF

  2009cited by this paper
• Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses.

  2009cited by this paper
• Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.

  2009cited by this paper
• Regulation of angiogenesis by oxygen and metabolism.

  2009cited by this paper
• Contribution of bone microenvironment to leukemogenesis and leukemia progression

  2009cited by this paper
• Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

  2009cited by this paper
• Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells.

  2008cited by this paper
• Novel Aspects of Glutamatergic Signalling in the Neuroendocrine System

  2008cited by this paper
• Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia

  2008cited by this paper
• Translation of the Philadelphia chromosome into therapy for CML.

  2008cited by this paper
• Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

  2008cited by this paper
• Antiangiogenesis in haematological malignancies

  2008cited by this paper
• Modes of resistance to anti-angiogenic therapy

  2008cited by this paper
• FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

  2008cited by this paper
• Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

  2007cited by this paper
• Molecular regulation of angiogenesis and lymphangiogenesis

  2007cited by this paper
• Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Angiogenesis and antiangiogenic therapy in hematologic malignancies.

  2007cited by this paper
• Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease.

  2006cited by this paper
• Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• VEGF receptor signalling ? in control of vascular function

  2006cited by this paper
• Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts

  2006cited by this paper
• United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

  2006cited by this paper
• Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

  2006cited by this paper
• Tie2 activation contributes to hemangiogenic regeneration after myelosuppression.

  2005cited by this paper
• The bone marrow vascular niche: home of HSC differentiation and mobilization.

  2005cited by this paper
• Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival.

  2005cited by this paper
• Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias

  2004cited by this paper
• Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.

  2004cited by this paper
• Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. - eScholarship

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity

  2003cited by this paper
• Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence

  2003cited by this paper
• Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition.

  2002cited by this paper
• Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment

  2002cited by this paper
• Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia.

  2002cited by this paper
• Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia

  2002cited by this paper
• BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

  2002cited by this paper
• Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

  2001cited by this paper
• Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity.

  2000cited by this paper
• Evidence of increased angiogenesis in patients with acute myeloid leukemia.

  2000cited by this paper
• Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.

  2000cited by this paper
• Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.

  2000cited by this paper
• Angiogenesis in myelodysplastic syndromes

  1999cited by this paper
• Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.

  1999cited by this paper
• Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.

  1997cited by this paper
• Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

  1996cited by this paper

• Understanding hairy cell leukemia in the context of mature B-cell neoplasms: tumor microenvironment and extracellular vesicle contribution to disease pathogenesis.

  2026cites this paper
• AdipoRon promotes angiogenesis in B-cell leukemia by modulating pro-angiogenic factors through AdipoR1

  2025cites this paper
• High-Dimensional Spatiotemporal Single-Cell and 3D Atlas of the Bone Marrow Microenvironment during Leukemic Progression

  2025cites this paper
• Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?

  2024cites this paper
• Single‐cell combined with bulk‐RNA data reveal a pattern related to angiogenesis in breast cancer patients: Individualized medicine

  2023cites this paper
• Bone marrow vasculature advanced in vitro models for cancer and cardiovascular research

  2023cites this paper
• Dual pH- and temperature-responsive poly(dimethylaminoethyl methacrylate)-coated mesoporous silica nanoparticles as a smart drug delivery system

  2023cites this paper
• Exploring RAB11A Pathway to Hinder Chronic Myeloid Leukemia-Induced Angiogenesis In Vivo

  2023cites this paper
• Vagus innervation in the gastrointestinal tumor: Current understanding and challenges.

  2023cites this paper
• Association of single nucleotide variants in VEGFA and KDR with the risk and angiogenic features of diffuse large B-cell lymphoma

  2023cites this paper
• Resistance to antiangiogenic treatments: A review

  2022cites this paper
• Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid

  2022cites this paper
• Antileukemia Activity and Mechanism of Platinum(II)-Based Metal Complexes

  2022cites this paper
• NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity

  2022cites this paper
• Dual Effects of Resveratrol on the Expression and Secretion of Angiogenic Factors

  2022cites this paper
• ZLM-7 Blocks Breast Cancer Progression by Inhibiting MDM2 via Upregulation of 14-3-3 Sigma

  2022cites this paper
• The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma

  2022cites this paper
• Gaucher disease – more than just a rare lipid storage disease

  2022cites this paper
• The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia

  2021cites this paper
• Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments

  2021cites this paper
• Leukaemia: a model metastatic disease

  2021cites this paper
• Blood Vessels and Peripheral Nerves as Key Players in Cancer Progression and Therapy Resistance

  2021cites this paper
• Dynamic responses of the haematopoietic stem cell niche to diverse stresses

  2020cites this paper
• Leukemia-on-a-chip: Dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche

  2020cites this paper
• Non-Coding RNAs as Cancer Hallmarks in Chronic Lymphocytic Leukemia

  2020cites this paper
• Angiogenesis Inhibition in Prostate Cancer: An Update

  2020cites this paper
• Gastric carcinogenesis: a comprehensive review of the angiogenic pathways

  2020cites this paper
• Anti‐VEGF DNA‐based aptamers in cancer therapeutics and diagnostics

  2020cites this paper
• Increased number of mast cells in the bone marrow of chronic myeloid leukemia may herald the pending myeloid transformation—the mast cell is an indicator of myeloid transformation

  2019cites this paper
• CMAR_A_190932 5033..5046

  2019cites this paper
• Kronik Miyelositer Lösemi-Opere Prostat Kanseri-Bilateral Plevral Efüzyon-Akciğer Kanserine Bağlı Yapılan Sağ Üst Lobektomi

  2019cites this paper
• Correlation of Intravoxel Incoherent Motion Parameters and Histological Characteristics From Infiltrated Marrow in Patients With Acute Leukemia

  2019cites this paper
• The Endothelium During Allogeneic Stem Cell Transplantation

  2019cites this paper
• Plausibility of trophoblastic-like regulation of cancer tissue

  2019cites this paper
• Long non-coding RNAs in hematological malignancies: translating basic techniques into diagnostic and therapeutic strategies

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1420 Vascular targeting for enhanced cancer immunotherapy

  2018cites this paper
• Aberrant bone marrow vascularization patterns in untreated patients with Gaucher disease type 1.

  2018cites this paper
• Role of WT1 in Ischaemic Angiogenesis

  2018influential citation
• Role of circulating endothelial cells and platelet microparticles as markers of angiogenesis in chronic myeloid leukemia

  2018cites this paper
• Placental growth factor promotes epithelial-mesenchymal transition-like changes in ARPE-19 cells under hypoxia

  2018cites this paper
• Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.

  2018cites this paper
• The Angiogenic Chemokines Expression Profile of Myeloid Cell Lines Co-Cultured with Bone Marrow-Derived Mesenchymal Stem Cells

  2018cites this paper
• Ecotopic viral integration site 1 (EVI1) transcriptionally targets talin1 (TLN1) and upregulates its expression in chronic myeloid leukemia

  2018cites this paper
• Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing

  2017cites this paper
• Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer

  2017cites this paper
• An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia

  2017influential citation
• Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells

  2017cites this paper
• Angiogenesis Status in Patients with Acute Myeloid Leukemia: From Diagnosis to Post-hematopoietic Stem Cell Transplantation

  2017cites this paper
• Beyond organoids: In vitro vasculogenesis and angiogenesis using cells from mammals and zebrafish.

  2017cites this paper
• Chapter Seven - Targeting the Bone Marrow Niche in Hematological Malignancies

  2017cites this paper
• Placental growth factor: What hematologists need to know.

  2017cites this paper
• Angiogenesis in Liquid Tumors: An In Vitro Assay for Leukemic‐Cell‐Induced Bone Marrow Angiogenesis

  2016cites this paper
• Targeting the angio-proteostasis network: Combining the forces against cancer.

  2016cites this paper
• Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma.

  2016cites this paper
• Targeting Angiogenesis in Cancer Treatments: Where do we Stand?

  2016cites this paper
• Suppression of HSP27 increases the anti-tumor effects of quercetin in human leukemia U937 cells

  2015cites this paper
• A Novel Image Analysis Methodology for the Evaluation of Angiogenesis in Matrigel Assays and Screening of Angiogenesis-Modulating Compounds

  2015cites this paper
• Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis

  2015cites this paper
• The prognostic significance of vascular endothelial growth factor expression in Wilms’ tumor and its relevance to WT1 expression

  2014cites this paper
• The role of vitamin D in dogs with Spirocerca lupi-associated neoplastic transformation

  2014cites this paper
• Mesenchymal Stem Cells: Pivotal Players in Hematopoietic Stem Cell Microenvironment

  2014cites this paper
• Imaging vascular development in zebrafish (Danio Rerio)

  2014cites this paper
• Placental growth factor in cancer

  2014cites this paper
• Angiogenesis and acute myeloid leukemia

  2014cites this paper
• Understanding the biology of reactive oxygen species and their link to cancer: NADPH oxidases as novel pharmacological targets

  2014cites this paper
• FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

  2014cites this paper
• HERG1 K+ channels on the leukemic cells mediated angiogenesis in vitro

  2014cites this paper
• Angiogenesis is increased in advanced haemophilic joint disease and characterised by normal pericyte coverage

  2014cites this paper
• The zebrafish as a model of vascular development and disease.

  2014cites this paper
• The endothelium in graft-versus-host disease and graft-versus-leukemia

  2013cites this paper
• Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells

  2013cites this paper
• VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia

  2013cites this paper
• ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia

  2013cites this paper
• Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells

  2013cites this paper
• The VEGF pathway in lung cancer

  2013cites this paper
• The Role of miRNA in Haematological Malignancy

  2013cites this paper
• Contribution of the intracellular cholesterol levels for the expression of VEGF-C and VEGFR-3 in acute myeloid leukemia

  2013cites this paper
• Understanding the Dynamics of Tumor Angiogenesis: A Systems Biology Approach

  2012cites this paper
• Tumor-associated macrophages and angiogenesis: a statistical correlation that could reflect a critical relationship in ameloblastoma.

  2012cites this paper
• Importance of local hypoxia on endothelial phenotype for an in vitro approach to bone marrow angiogenesis.

  2012cites this paper
• Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis

  2012cites this paper
• Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy

  2012cites this paper
• Intracellular and Extracellular miRNAs in Regulation of Angiogenesis Signaling.

  2012cites this paper
• Prognostic impact of δ-like ligand 4 and Notch1 in acute myeloid leukemia.

  2012cites this paper
• Label‐free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance

  2012cites this paper